- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Braveheart Bio charges past expectations with $382.5M IPO to fund cardio drug from Hengrui | 1 | FierceBiotech | ||
| Do | Cardiovascular diseases biotech Braveheart Bio prices upsized IPO at $18, above the range | 1 | Renaissance Capital | ||
| Do | Braveheart Bio prices $382.5M IPO at $18 per share | 1 | Investing.com | ||
| Do | Braveheart Bio, Inc.: Braveheart Bio Announces Pricing of Upsized Initial Public Offering | 63 | GlobeNewswire (Europe) | SAN FRANCISCO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy... ► Artikel lesen | |
| Mo | Braveheart Bio, Inc. - 8-A12B, Registration of securities | 1 | SEC Filings | ||
| 30.07. | Braveheart Bio, Attovia seek $275M and $182M in U.S. IPOs | 1 | Seeking Alpha | ||
| BRAVEHEART BIO Aktie jetzt für 0€ handeln | |||||
| 30.07. | Attovia, Braveheart Bio and Vogenx seek more than $500M across trio of IPOs | 1 | FierceBiotech | ||
| 30.07. | Cardiovascular diseases biotech Braveheart Bio sets terms for $300 million IPO | 1 | Renaissance Capital | ||
| 30.07. | Braveheart Bio, Inc. - S-1/A, General form for registration of securities | 3 | SEC Filings | ||
| 16.07. | Two more biotechs, Attovia and Braveheart Bio, join the IPO line | 1 | pharmaphorum | ||
| 15.07. | Braveheart Bio aims for freedom with IPO to support Hengrui-licensed cardio asset | 13 | FierceBiotech | ||
| 15.07. | Braveheart Bio, Attovia, Apnimed join gene therapy firm Scribe Therapeutics in July IPO rush | 3 | Seeking Alpha | ||
| 15.07. | Braveheart Bio, Attovia join next wave of biotech IPOs | 1 | BioPharma Dive | ||
| 15.07. | Cardiovascular diseases biotech Braveheart Bio files for a $100 million IPO | 1 | Renaissance Capital | ||
| 14.07. | Braveheart Bio, Inc. - S-1, General form for registration of securities | 1 | SEC Filings |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APOGEE THERAPEUTICS | 134,49 | +0,19 % | AbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimates | ||
| PRAXIS PRECISION MEDICINES | 369,91 | +15,88 % | Praxis Precision Medicines, Inc. - 10-Q, Quarterly Report | ||
| QIAGEN | 36,140 | -0,63 % | Ihre wichtigsten Termine: Frische Zahlen von Ebay, Eli Lill, Allstate, Infineon, Novo Nordisk, Walt Disney | Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine 06:45 Uhr, Deutschland: Basler... ► Artikel lesen | |
| ERASCA | 18,270 | -1,88 % | Erasca, Inc.: Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100% Monotherapy has been generally well-tolerated... ► Artikel lesen | |
| VERA THERAPEUTICS | 32,020 | +5,50 % | Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen | |
| CREATIVE MEDICAL TECHNOLOGY | 1,160 | +76,72 % | Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz, CELZ-101 and CELZ-201 Diabetes Platforms | PHOENIX, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company advancing regenerative... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 26,400 | -2,58 % | Starke Zoryve-Umsätze: Guggenheim hebt Kursziel für Arcutis an | ||
| ENLIVEN THERAPEUTICS | 60,27 | +0,95 % | Guggenheim lowers Enliven Therapeutics stock price target to $78 | ||
| AMYLYX PHARMACEUTICALS | 24,200 | +10,76 % | Amylyx anticipates Phase III LUCIDITY top-line data in late August or early September with $250.8M cash runway into 2028 | ||
| TARSUS PHARMACEUTICALS | 65,42 | +6,74 % | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position | Adds a potential blockbuster opportunity with gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt disease, one of... ► Artikel lesen | |
| JANUX THERAPEUTICS | 16,100 | +0,62 % | Janux Therapeutics, Inc. - 10-Q, Quarterly Report | ||
| CG ONCOLOGY | 74,83 | +3,33 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| ADMA BIOLOGICS | 10,055 | +8,59 % | Kehoe Law Firm, P.C.: ADMA Biologics (ADMA) Shareholder Alert: Kehoe Law Firm Investigates Potential Fiduciary Duty Breaches | Philadelphia, Pennsylvania--(Newsfile Corp. - August 5, 2026) - Kehoe Law Firm, P.C. is investigating whether certain officers and directors of ADMA Biologics, Inc. ("ADMA," "ADMA Biologics," or... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,175 | +0,16 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program | Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated... ► Artikel lesen | |
| ZENAS BIOPHARMA | 32,170 | +0,97 % | Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD | - BLA submission based on positive results from Phase 3 INDIGO trial - WALTHAM, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas," "Zenas BioPharma" or the "Company") (Nasdaq:... ► Artikel lesen |
BRAVEHEART BIO INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 30,290 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BRAVEHEART BIO INC finden Sie auf Wallstreet Online.